Connect with us

Technology

RaySearch Laboratories to present ongoing development in liver ablation therapy* at RSNA 2024

Published

on

STOCKHOLM, Nov. 29, 2024 /PRNewswire/ — RaySearch will be exhibiting its advanced software solutions at RSNA in Chicago, Illinois, December 1 – 4. RSNA is the largest conference show in the field of radiology which opens new horizons for the company. Participants can book demonstrations of the module, which is ongoing development, for liver ablation treatments in RaySearchs’s booth #8340 during the event.

LIVER ABLATION – EXPANDING SUPPORT OF TREATMENTS

The Liver Ablation module will include tools such as automatic structure segmentation using deep learning, virtual applicator placement and estimation of the ablation zone. Applicator placement verification and post-treatment verification based on deformable registration will be supported as well.

SCIENCE SESSION AT RSNA

RaySearch would like to invite you to the interventional radiology session where Bruno C. Odisio from MD Anderson will present the latest results from the COVER-ALL study.

This randomized trial evaluates the use of a novel ablation confirmation method consisting of biomechanical deformable image registration with AI-based autosegmentation and its impact on minimal ablative margins.

Time and date: 3 December 2024 at 9:30-10:30 am CST

Location: N227B

Additionally, RayStation®* treatment planning system, RayCare®* oncology information system, the cloud-based oncology analytics system RayIntelligence®, and a new solution DrugLog®*, verification device for compounded injectable medications, will be presented.

DRUGLOG – CONTROL IN EVERY COMPOUND, CONFIDENCE IN EVERY PATIENT

DrugLog is a reliable, stand-alone solution for reducing compounding errors. It verifies the identity and concentration of compounded injectables before they are administered to a patient receiving a chemotherapy treatment. DrugLog ensures that pharmacists can confidently deliver personalized medications, tailored to each patient to enhance treatment success.

Johan Löf, founder and CEO, RaySearch: “I am very much looking forward to meeting both existing and new customers at RSNA and presenting the exciting research results regarding liver ablation and our product portfolio, including DrugLog which represents an expansion of our offering, outside of radiation therapy.”

ABOUT RAYSEARCH

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line is RayIntelligence®. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. 

RaySearch’s software has been sold to over 1,000 clinics in 43 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.

ABOUT RAYSTATION

RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.

ABOUT RAYCARE

The RayCare®* oncology information system (OIS) is designed to support the many complex logistical challenges faced by today’s oncology clinics. RayCare is closely integrated with RayStation®* and provides seamless access to all the powerful planning tools in RayStation and RayCommand®. The system efficiently coordinates activities in radiation therapy and offers advanced features for clinical workflow automation, and adaptive radiation therapy. RayCare responds to the demand from clinics for a more user-friendly and workflow-oriented information system that can support the cancer care of the future.

ABOUT RAYINTELLIGENCE

Data-driven oncology represents a new era in healthcare. RayIntelligence® is an innovative cloud-based oncology analytics system that gives meaning to data, empowering cancer centers to reach new levels of personalized care through insights based on clinical data.

* Some functionality is under development (not clinical) or subject to regulatory clearance in some markets.

FOR MORE INFORMATION, PLEASE CONTACT: 

Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) 
Telephone: +46 (0) 8 510 530 00 
johan.lof@raysearchlabs.com  

Learn more about us on:
LinkedIn
YouTube
X

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/raysearch-laboratories/r/raysearch-laboratories-to-present-ongoing-development-in-liver-ablation-therapy–at-rsna-2024,c4073654

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/raysearch-laboratories-to-present-ongoing-development-in-liver-ablation-therapy-at-rsna-2024-302318761.html

SOURCE RaySearch Laboratories

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

CEFALY to Demonstrate Its Migraine Treatment Device at the American College of Obstetricians and Gynecologists’ Annual Clinical & Scientific Meeting

Published

on

By

DARIEN, Conn., May 13, 2025 /PRNewswire/ — Medical device maker CEFALY Technology will be conducting live demonstrations of its clinically proven neuromodulation treatment for migraine at Booth 102 at the ACOG Annual Clinical & Scientific Meeting May 16-18, 2025 in Minneapolis, Minnesota.

With more than 60,000 members, the American College of Obstetricians and Gynecologists is the nation’s premier professional membership organization for OB/GYNs. Its Annual Clinical and Scientific Meeting is the country’s largest event dedicated to obstetric and gynecological healthcare.

“Migraine is a complex and often disabling neurological disorder that affects one in five women,” said Jen Trainor-McDermott, CEO of CEFALY Technology. “We look forward to presenting CEFALY’s FDA-cleared migraine treatment device to this esteemed group of clinicians as an effective, safe, and drug-free option for their patients.” 

Migraine predominantly affects women in their childbearing years, yet finding ways to treat migraine safely during pregnancy has been a persistent challenge. Certain commonly used acute and preventative migraine medications are not advised for use during pregnancy, due to the risk of birth defects or other harm to the developing fetus.

In the American Registry of Migraine Research observational study, approximately 20% of women with migraine chose to avoid pregnancy due to migraine. These women cited many reasons for doing so: They believed that their migraine would be worse during pregnancy, they believed the disability caused by migraine would make pregnancy difficult, and they feared migraine medications would negatively affect their child’s development.

Neuromodulation has emerged as a promising non-pharmaceutical treatment option. “While at this time data is limited regarding the true safety of neuromodulation in pregnancy, studies conducted thus far on the available FDA- approved devices for migraine and relevant devices with similar mechanisms of action do not appear to pose a harm to the pregnant patient or the developing fetus,” according to a recent review in Current Pain and Headache Reports

A non-invasive medical device that’s worn on the forehead, CEFALY targets the trigeminal nerve to relieve migraine pain and prevent future attacks. Many women have used CEFALY for migraine relief during pregnancy with no known serious adverse effects. However, the safety and efficacy of CEFALY have not been evaluated in pregnant women. 

CEFALY is currently conducting an online survey registry to help researchers understand the benefits of non-medication options for migraine relief in pregnant women. Michael A. L. Johnson, MD, Medical Affairs Advisor for CEFALY Technology, will be available to discuss the pregnancy registry with attendees, as well as answering questions about the clinical relevance of the CEFALY device. 

CEFALY will offer attendees the chance to try the CEFALY Connected device, so they can experience the sensation of gentle neurostimulation for themselves. CEFALY will also invite clinicians to participate in its online CEFALY Certified education program, which covers the basics of eTNS (external trigeminal nerve stimulation) treatment for migraine.

“CEFALY hopes to build strong relationships with ACOG’s members as we work together to offer women a safe, non-pharmacological treatment for migraine,” said Trainor-McDermott. 

About CEFALY Technology:
CEFALY Technology is the maker of CEFALY, an FDA-cleared, over-the-counter wearable medical device clinically proven to help reduce migraine frequency and relieve migraine pain. CEFALY Technology is a Belgium-based company with its U.S. offices based in Darien, Conn., specializing in electronics for medical applications. CEFALY Technology’s mission is to provide innovative, ever-evolving technology that enables people with migraine to take control of their treatment and live happier, healthier lives.

Learn more about CEFALY by visiting CEFALY.com and following us on Facebook, Twitter, LinkedIn, Instagram and TikTok.

Media Contact:
CEFALY
Jen Trainor-McDermott
CEO
j.trainor@cefaly.com

View original content:https://www.prnewswire.com/news-releases/cefaly-to-demonstrate-its-migraine-treatment-device-at-the-american-college-of-obstetricians-and-gynecologists-annual-clinical–scientific-meeting-302453933.html

SOURCE CEFALY Technology

Continue Reading

Technology

nTop to Host 2025 Computational Design Summit, Spotlighting Engineering Breakthroughs in Aerospace and Manufacturing

Published

on

By

One-day event to explore how AI, simulation, and computational design are accelerating innovation across aerospace, turbomachinery, and advanced manufacturing

LOS ANGELES, May 13, 2025 /PRNewswire-PRWeb/ — nTop, the leader in computational design software for high-performance engineering, is excited to announce the 2025 nTop Computational Design Summit (nCDS), taking place on June 24, 2025, in Los Angeles. The one-day event will bring together industry experts, innovative customers, and nTop executives to explore how computational design, AI, and machine learning are transforming engineering and accelerating product development—delivering faster, smarter, and more adaptable solutions to complex design challenges.

“nCDS is an opportunity to showcase how computational design and AI are changing the way products are developed and brought to market—helping engineers shorten design cycles, improve performance, and meet increasingly complex requirements.” – Bradley Rothenberg, CEO and founder, nTop

“At nTop, we’re committed to pushing the boundaries of what’s possible in engineering,” said Bradley Rothenberg, CEO and founder, nTop. “nCDS is an opportunity to showcase how computational design and AI are changing the way products are developed and brought to market—helping engineers shorten design cycles, improve performance, and meet increasingly complex requirements.”

Engineering organizations are navigating a generational shift, driven by the need for faster development timelines, deeper simulation integration, and AI-enhanced automation. As industries embrace digital transformation, tools that enable rapid iteration, performance optimization, and scalable workflows are becoming essential. nCDS reflects this momentum, bringing together leading voices in high-performance engineering to explore how computational design is reshaping the future of product development.

Featured speakers include:

Carlos Mendez, Staff Opto-Mechanical Engineer, Lockheed MartinMichael Emory, Product Manager, LuminaryMarkus Lempke, Computational Design for AM, Siemens EnergyAndy Kappers, Mechanical Engineer, Siemens EnergyJan Vandenbrande, formerly DARPA, BoeingGeorge Allen, nTop Fellow

Geared towards engineers who want to learn about the tools and methods for applying computational design to their work, nCDS will feature keynote presentations, engineering case studies, partner demonstrations, and hands-on training sessions. Attendees will gain insights into the latest advancements in computational design, including AI-driven engineering workflows, simulation efficiency breakthroughs, and the future of aircraft and turbomachinery design.

Participants will see how leading engineering teams generate validated design variants—complete with geometry and physics results—in hours, rather than weeks. Interactive sessions will demonstrate how computational design enables faster iteration, deeper simulation integration, and better product outcomes across every stage of development.

Event Details:

Date: June 24, 2025

Time: 10:30 AM6:30 PM

Location: Hudson Loft, 1200 S Hope St., Los Angeles, CA 90015

Join engineers from General Atomics, Lockheed Martin, Northrop Grumman, Siemens Energy, and more at nCDS as they explore computational design and the future of AI-driven engineering. Register for the event here: https://www.ntop.com/ncds-2025/.

About nTop

nTop is the computational design platform for high-performance engineering. Built for teams solving the world’s hardest engineering challenges—from hypersonics to heat exchangers—nTop combines GPU-accelerated modeling, in-the-loop simulation, and automation to help engineers generate and evaluate thousands of design variants, including geometry and physics results, in hours, not weeks. Trusted by over 450 teams across aerospace, defense, automotive, and energy, nTop redefines how design is done, turning engineering logic into reusable workflows, enabling rapid exploration of the design space, and shortening product cycles from concept to production. For more information, visit www.ntop.com.

Media Contact

Maya Komadina, nTop, 1 9179839257, press@ntop.com, www.ntop.com 

View original content to download multimedia:https://www.prweb.com/releases/ntop-to-host-2025-computational-design-summit-spotlighting-engineering-breakthroughs-in-aerospace-and-manufacturing-302452085.html

SOURCE nTop

Continue Reading

Technology

Cruisebound Wins “Online Booking Innovation of the Year” in TravelTech Breakthrough Awards

Published

on

By

NEW YORK, May 13, 2025 /PRNewswire/ — Cruisebound, the online cruise agency reinventing how travelers book cruises, was just named Online Booking Innovation of the Year in the TravelTech Breakthrough Awards–a leading global market intelligence platform recognizing excellence in travel and hospitality technology.

As cruising grows in popularity, customers’ expectations are higher than ever.

This year’s awards received thousands of nominations from more than 14 countries. Cruisebound was chosen for its fresh, user-friendly technology and its commitment to reinventing the cruise booking industry. By constantly testing new ideas and fine-tuning the customer experience, Cruisebound has made it easier than ever for travelers to search, compare, book, and earn rewards on cruises from all major lines—whether online or via its mobile app—while still offering access to real human support.

“We’re absolutely thrilled to receive this recognition from TravelTech Breakthrough,” said Pierre-Olivier Lepage, CEO of Cruisebound. “Cruising has long been one of the most complex travel products to book online. Our team set out to change that—to make the process intuitive, stress-free, and still personal. This award is a huge nod to the expertise, creativity, and care we put into everything we build.”

As cruising grows in popularity, thanks in part to a slew of new ship and destination experiences, plus its status as one of the best value-per-dollar products in the travel industry, customers’ expectations are higher than ever. Cruisebound is leading the way and breaking down barriers left by legacy systems. By building a modern cruise booking experience—one that feels as easy as booking a flight or hotel—Cruisebound brings more brand-new customers to the industry every day.

The TravelTech Breakthrough Awards honor the most forward-thinking companies and innovations shaping the future of travel. Their mission is to spotlight user-first design and technologies that drive both impact and growth across the industry.

For more on Cruisebound, visit www.cruisebound.com.

About Cruisebound

Cruisebound, founded in 2022, helps consumers find and compare cruises from every major cruise line to find the best fit for vacation needs. Comprehensive inventory with real-time pricing and instant booking, customer service team available to answer questions, and no booking fees sets Cruisebound apart from competitors. Whether it’s a multigenerational family trip to Mexico with Royal Caribbean, an anniversary celebration in the Mediterranean on Virgin Voyages or a once-in-a-lifetime Alaska adventure with Norwegian Cruise Line, Cruisebound makes it easy to discover and book your perfect cruise. For more information, or to book your next cruise, visit: www.cruisebound.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cruisebound-wins-online-booking-innovation-of-the-year-in-traveltech-breakthrough-awards-302453063.html

SOURCE Cruisebound, Inc.

Continue Reading

Trending